Abstract:Hengfeng Liao 1, 2 , Yue Gao 1, 2 , Chunfang Lian 1, 2 , Yun Zhang 1, 2 , Bangyuan Wang 1, 2 , Yanfang Yang 1, 2 , Jun Ye 1, 2 , Yu Feng 1, 2 , Yuling Liu 1, 2 1 State Key Laboratory of Bioactive substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China; 2 Beijing Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, People's Republic of China Correspondence: Yuling Liu State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 1 Xiannongtan Street, Beijing 100050, People's Republic of China Tel +86 108 928 5188 Fax +86 108 928 5190 Email ylliu@imm.ac.cn Purpose: The aims of this study were to prepare a baicalein self-microemulsion with baicalein-phospholipid complex as the intermediate (BAPC-SMEDDS) and to compare its effects with those of conventional baicalein self-microemulsion (CBA-SMEDDS) on baicalein oral absorption and lymphatic transport. Methods: Two SMEDDS were characterized by emulsifying efficiency, droplet size, zeta potential, cloud point, dilution stability, physical stability, and in vitro release and lipolysis. Different formulations of 40 mg/kg baicalein were orally administered to Sprague-Dawley rats to investigate their respective bioavailabilities. The chylomicron flow blocking rat model was used to evaluate their lymphatic transport. Results: The droplet sizes of BAPC-SMEDDS and CBA-SMEDDS after 100x dilution were 9.6±0.2 nm and 11.3±0.4 nm, respectively. In vivo experiments indicated that the relative bioavailability of CBA-SMEDDS and BAPC-SMEDDS was 342.5% and 448.7% compared to that of free baicalein (BA). The AUC 0–t and C max of BAPC-SMEDDS were 1.31 and 1.87 times higher than those of CBA-SMEDDS, respectively. The lymphatic transport study revealed that 81.2% of orally absorbed BA entered the circulation directly through the portal vein, whereas approximately 18.8% was transported into the blood via lymphatic transport. CBA-SMEDDS and BAPC-SMEDDS increased the lymphatic transport ratio of BA from 18.8% to 56.2% and 70.2%, respectively. Therefore, self-microemulsion not only significantly improves oral bioavailability of baicalein, but also increases the proportion lymphatically transported. This is beneficial to the direct interaction of baicalein with relevant immune cells in the lymphatic system and for proper display of its effects. Conclusion: This study demonstrates the oral absorption and lymphatic transport characteristics of free baicalein and baicalein SMEDDS with different compositions. This is of great significance to studies on lymphatic targeted delivery of natural immunomodulatory compounds. Keywords: SMEDDS, phospholipid complex, baicalein, oral bioavailability, lymphatic transport

Improved Bioavailability and Hepatoprotective Activity of Baicalein Via a Self-assembled Solutol HS15 Micelles System

Enhancing The Oral Bioavailability Of Baicalein Via Solutola (R) Hs15 And Poloxamer 188 Mixed Micelles System

Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes

Diammonium Glycyrrhizinate-Based Micelles for Improving the Hepatoprotective Effect of Baicalin: Characterization and Biopharmaceutical Study

Hepatic Metabolism and Disposition of Baicalein via the Coupling of Conjugation Enzymes and Transporters— In Vitro and In Vivo Evidences

Hepatoprotective Effect of Baicalein Against Acetaminophen-Induced Acute Liver Injury in Mice

Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal.

Antifibrotic Effects of Chronic Baicalein Administration in a CCl4 Liver Fibrosis Model in Rats

Baicalin and Its Nanoliposomes Ameliorates Nonalcoholic Fatty Liver Disease Via Suppression of TLR4 Signaling Cascade in Mice

Preparation, Characterization, Pharmacokinetics and Biodistribution of Baicalin-Loaded Liposome on Cerebral Ischemia-Reperfusion after i.v. Administration in Rats

Nanostructured Lipid Carriers for Oral Delivery of Baicalin: in Vitro and in Vivo Evaluation

Characterization and Bioavailability Study of Baicalin-mesoporous Carbon Nanopowder Solid Dispersion

Inhibition of Oxidative Stress and ALOX12 and NF-B Pathways Contribute to the Protective Effect of Baicalein on Carbon Tetrachloride-Induced Acute Liver Injury

Baicalin Liposome Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Mice Via Inhibiting TLR4/JNK/ERK/NF-κB Pathway

Baicalin Liposome Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Mice via Inhibiting TLR4/JNK/ERK/NF- κ B Pathway

Preparation, Characterization and in Vivo Evaluation of Formulation of Baicalein with Hydroxypropyl-Beta-Cyclodextrin

Inhibition of Oxidative Stress and ALOX12 and NF-κB Pathways Contribute to the Protective Effect of Baicalein on Carbon Tetrachloride-Induced Acute Liver Injury

Preparation, optimization, characterization and in vitro release of baicalein-solubilizing glycyrrhizic acid nano-micelles

Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems

Exploration of the potential mechanism of Baicalin for hepatic fibrosis based on network pharmacology, gut microbiota, and experimental validation

Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects